National AFFF PFAS Toxic Tort: Firefighter Cancer, Military Base Contamination, and the Fight for Accountability
If you are reading this, you may be a firefighter who spent years pulling the nozzle on AFFF — the white foam that smothered jet fuel fires so effectively it became the military’s default — and you are now sitting with a cancer diagnosis that came out of nowhere. Or you may live near a base where the water tasted fine for years, and a letter just arrived telling you the aquifer is contaminated. Or you may have buried someone whose kidney cancer or testicular cancer never made sense until the word “PFAS” entered your life. Whatever brought you here, one thing is already true: the companies that made this foam and the institutions that deployed it for decades knew more, and knew it earlier, than they told you. That is where your case begins, and that is what we are built to fight.
We are Attorney911 — The Manginello Law Firm. We handle toxic tort claims and the catastrophic-injury and wrongful-death cases that grow out of them. What follows is everything you need to understand about AFFF and PFAS contamination right now: what the law allows you to do, what the evidence looks like, how fast it is disappearing, what your case may be worth, and what the other side is already doing to make this harder than it should be. None of this is speculation. Every fact in this page is grounded in verified federal regulation, peer-reviewed science, and the public record of the litigation that is moving through the courts right now.
What Happened: The National PFAS Contamination Crisis
More than 700 U.S. Department of Defense installations either have or are likely to have elevated levels of per- and polyfluoroalkyl substances — PFAS — in their water or soil. The contamination came from aqueous film-forming foam, AFFF, used for decades to put out jet fuel fires and to train firefighters in the practice. The DOD needs to remove more than 2 million gallons of AFFF concentrate across its facilities, plus another 1.5 million gallons of rinsate — the contaminated washwater left over from cleaning fire trucks and airplane hangars before the transition to a new fluorine-free foam called F3 can be completed. Millions more gallons sit at airports, municipal firefighting sites, and other non-military facilities.
Congress has mandated that the DOD phase out PFAS in AFFF by October 1, 2026, with exceptions for ships and research. Some bases are ahead — Wright-Patterson Air Force Base in Ohio completed its AFFF removal at a cost of about $370,000 and finished transitioning to F3 in July 2024. But a public investigation found that the DOD has delayed PFAS cleanup timelines at 178 sites, pushing remediation back between one and twenty years. The DOD’s own PFAS progress report, which tracks assessments at 723 installations, was last updated in September 2025. When asked whether AFFF removal has been completed at any U.S. military sites, a DOD spokesman said only that the department “continues to remove AFFF from its installations” and plans to update its website “in the future.”
Meanwhile, the contamination is not static. At Joint Base Cape Cod, where the water table lies less than ten feet below the surface, groundwater contamination is actively spreading toward nearby communities including Falmouth and Mashpee. Harvard researchers found that precursors to PFAS — the chemical building blocks that sit in the soil at fire training areas — are abundant at military facilities, and when nitrate-oxidizing bacteria interact with those precursors, they convert them into PFAS compounds, typically PFBS and PFHxS, which then trickle into the groundwater.
“The majority of what you find in AFFF is the precursor. There was a lot of AFFF used, so there are a ton of precursors in the soil at the fire training areas. They’re basically trickling into the groundwater, but what you’re seeing in the actual water around these bases is such a tiny fraction of the overall burden. This is going to go on for a really long time.”
That is the Harvard environmental chemistry researcher describing the contamination at Joint Base Cape Cod. Her team concluded that without remediation, elevated exposure to PFAS near more than 300 military facilities could persist for centuries. The contamination you are dealing with today is not a historical event that ended. It is an active, ongoing chemical conversion that is generating more PFAS in the soil beneath the places where people live and work.
The DOD recently lifted its moratorium on incineration as a disposal method, issuing updated guidance in February that includes incineration among approved methods alongside granulated activated carbon, hazardous waste landfills, underground injection, and thermal desorption. A study at one of only two DOD-authorized incineration facilities found the system can destroy 99.9999% of PFAS. But the remediation market is still finding its footing — the total market for PFAS treatment, including soil remediation and wastewater and drinking water treatment, is expected to reach more than $100 billion over the next thirty years. That figure tells you something about the scale of what was done to the environment, and about the scale of what the companies that made this foam may be asked to pay for.
Who Is at Risk: Firefighters, Military Personnel, and Communities Near Contaminated Installations
Two populations bear the heaviest exposure burden, and the legal path for each is different.
Military and civilian firefighters who directly handled AFFF face the most concentrated occupational exposure. These are the men and women who sprayed the foam in training exercises — sometimes weekly, sometimes daily — for years or decades. AFFF was designed to be mixed with water and applied at high volume, which means the PFAS compounds in the foam were absorbed through skin contact, inhalation of aerosolized foam, and ingestion from contaminated equipment. Firefighters who cleaned trucks, flushed lines, and maintained AFFF systems had sustained, repeated contact with the concentrate itself. The military has awarded contracts to support the transition to fluorine-free agents for about 7,000 mobile assets and 1,000 facilities, but for the firefighters who already spent careers working with the old foam, the exposure has already happened and the compounds are already in their blood.
Community members who live near contaminated military installations face a different exposure pathway — drinking water. When AFFF was used in training areas, the PFAS compounds seeped into the soil and reached the groundwater, which feeds the aquifers that supply private wells and municipal water systems. At Wright-Patterson Air Force Base, even after AFFF removal was completed, three of twenty-two private drinking water wells near the facility still showed levels of PFOA and PFOS exceeding maximum contaminant levels as of 2024. The base has been treating water with a portable granulated activated carbon system and discharging to the city of Fairborn’s publicly-owned treatment works, but the private wells are the residents’ problem, and the contamination in the aquifer does not respond to cleanup the way a surface spill does.
The geographic scope is national. PFAS and AFFF contamination is documented at over 700 DOD sites, with specific hotspots including Joint Base Cape Cod in Massachusetts, Wright-Patterson Air Force Base in Ohio, Joint Base Elmendorf-Richardson in Alaska, and six established or suspected sites in New Mexico. New Mexico’s state government added AFFF to its state hazardous waste list and sued the DOD to try to force it to stop non-emergency AFFF use and compensate affected landowners. New Jersey launched a major AFFF collection program through its Department of Environmental Protection. The contamination is everywhere the military trained with foam, and the communities surrounding those bases are the downstream casualties.
The Health Conditions Linked to PFAS Exposure
PFAS are called “forever chemicals” because they do not break down. They are persistent in the environment and they are persistent in the human body. PFAS compounds bind to serum proteins and concentrate in the liver and kidneys. They are not metabolized. They have long human half-lives — measured in years, not days. Some PFAS compounds have estimated half-lives of two to seven years in the human body, which means that even after exposure stops, the compounds remain in the blood at measurable levels for years.
The C8 Science Panel — a group of independent epidemiologists who studied the health effects of PFOA contamination in the Mid-Ohio Valley — found “probable links” between PFOA and six conditions: kidney cancer, testicular cancer, high cholesterol, thyroid disease, pregnancy-induced hypertension, and ulcerative colitis. That research is the scientific backbone of much of the PFAS personal-injury litigation. The International Agency for Research on Cancer — the world’s leading cancer-science authority — classified PFOA as Group 1, carcinogenic to humans, and PFOS as Group 2B, possibly carcinogenic to humans.
The conditions most commonly pursued in AFFF and PFAS personal-injury litigation include:
- Kidney cancer — linked to PFOA exposure through the C8 Science Panel’s probable-link finding; the kidneys are a target organ because PFAS concentrates there
- Testicular cancer — linked to PFOA exposure through the C8 Science Panel; one of the two cancers with the strongest PFAS association
- Thyroid disease — including thyroid cancer and autoimmune thyroid disease; PFAS disrupts endocrine function
- Ulcerative colitis — a chronic inflammatory bowel disease linked to PFOA through the C8 Science Panel
- Pregnancy-induced hypertension — including preeclampsia, linked to PFOA exposure
- Infertility and reproductive harm — PFAS has been associated with reduced fertility and pregnancy complications
The diagnostics for PFAS-linked disease are condition-specific. Kidney cancer is diagnosed through renal imaging (CT, MRI, ultrasound) and biopsy. Testicular cancer through ultrasound and tumor markers. Thyroid disease through thyroid function panels and imaging. Ulcerative colitis through colonoscopy and biopsy. The PFAS exposure itself is documented through serum PFAS testing — a blood test that measures the concentration of specific PFAS compounds in the bloodstream. This test is the single most important piece of objective exposure evidence in a PFAS personal-injury case, and there is a clock on it.
The Law: CERCLA, EPA Standards, and the Discovery Rule
Three federal legal frameworks govern AFFF and PFAS litigation: the EPA’s drinking-water regulations, the CERCLA hazardous-substance designation, and the multidistrict litigation consolidation in federal court.
EPA Drinking-Water Standards
In April 2024, the EPA finalized Maximum Contaminant Levels for PFOA and PFOS at 4.0 parts per trillion each — a number so small it is roughly equivalent to a single drop of water spread across twenty Olympic swimming pools. The EPA set the health-based Maximum Contaminant Level Goals for PFOA and PFOS at zero, meaning the agency found no threshold below which there is no health risk. The compliance deadline for these standards is April 2029, though the EPA has proposed extending it to 2031.
The EPA also set individual MCLs for PFHxS, PFNA, and HFPO-DA (GenX chemicals) at 10 parts per trillion, and a Hazard Index of 1 for mixtures. However, in May 2026, the EPA proposed rescinding the limits for PFHxS, PFNA, GenX, and the Hazard Index mixture, while keeping the PFOA and PFOS standards. This rescission is proposed, not final. What matters for your case is that the science linking these compounds to disease did not change when the paperwork did. The C8 Science Panel’s probable-link findings and the IARC classifications remain intact regardless of which drinking-water limit is in flux.
CERCLA Hazardous Substance Designation
In May 2024, the EPA designated PFOA and PFOS as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act — CERCLA, the Superfund law. This designation, effective July 8, 2024, established a default reportable quantity of one pound: any entity that releases a pound or more of PFOA or PFOS in any 24-hour period must report those releases to the National Response Center and state and local emergency authorities.
“EPA established the default reportable quantity of one pound for releases of PFOA or PFOS, or their salts and structural isomers. Any entity that releases a pound or more… in any 24-hour period must report those releases consistent with CERCLA 103 and EPCRA 304.”
The CERCLA designation matters for your case because it creates a federal framework for contamination liability and cost recovery. CERCLA liability is strict, joint-and-several, and retroactive — meaning a company does not have to be proven careless to be responsible for cleanup, and the liability reaches conduct from decades ago. If a company owned the site, ran it, made the waste, or hauled it there, it can be made to pay for the cleanup. The only statutory defenses are act of God, act of war, or the act of a third party. For the AFFF manufacturers, “we followed the rules at the time” is not a CERCLA defense.
The Discovery Rule and the Statute of Limitations
The deadline to file a toxic tort lawsuit varies by state — typically between two and six years for personal injury claims. But in toxic exposure cases, most states apply the discovery rule, which tolls the statute of limitations until the plaintiff knew or reasonably should have known of the injury and its connection to the exposure. A firefighter diagnosed with kidney cancer at age 55 who spent twenty years handling AFFF may not have connected the diagnosis to the foam until recently. Under the discovery rule, the clock may start running from the date of diagnosis or the date the connection was reasonably discoverable — not from the date of exposure decades ago.
This is critical because PFAS-related diseases have long latency periods. The exposure may have happened twenty years ago, but the cancer may have been diagnosed last year. The law built the delay into the deadline because the disease built the delay into the body.
However, there is an important caveat. Some states impose an outer deadline called a statute of repose that can cut off a claim even before discovery. The discovery rule does not defeat a repose statute. Whether a repose statute applies in your state is a question that must be answered by an attorney who knows your jurisdiction’s current law. Never assume you have plenty of time — and never assume you are too late. Both assumptions can cost you the case.
If your claim runs against the federal government directly — for instance, against the DOD under the Federal Tort Claims Act — there are additional federal deadlines. Under the FTCA, you must file a written administrative claim (a Standard Form 95) with the appropriate federal agency within two years of the claim’s accrual. If the agency denies the claim, you have only six months to file suit in federal court. Miss either deadline and the claim is “forever barred,” in the statute’s own words. But the primary path for most AFFF personal-injury plaintiffs is through the MDL against the foam manufacturers, not through FTCA claims against the government.
The AFFF MDL: How the Federal Mass Tort Works
Thousands of AFFF personal-injury, wrongful-death, and property-damage claims are consolidated in a multidistrict litigation — MDL No. 2873, In re: Aqueous Film-Forming Foams Products Liability Litigation — in the U.S. District Court for the District of South Carolina, before Judge Richard M. Gergel. As of mid-2026, more than 15,000 actions were pending in this MDL.
An MDL is not a class action. Each plaintiff keeps an individual case. The MDL simply centralizes pretrial proceedings — discovery, motion practice, expert challenges — so that the shared factual and scientific questions are resolved once instead of thousands of times. At some point, individual cases may be selected as bellwether trials — test cases that go to verdict and establish settlement value benchmarks for the remaining inventory. The first AFFF personal-injury bellwether was selected to focus on kidney cancer and was set for October 2025, but was postponed after the court identified a large backlog of unfiled cases. The schedule is actively moving, and anyone with a potential claim should not wait to see how the bellwether process unfolds before getting their case filed and their evidence preserved.
The defendants in the AFFF MDL include the major manufacturers of PFAS-containing firefighting foam. These are some of the largest chemical companies in the world, and they have already reached substantial settlements on the public-water-provider side: 3M agreed to pay approximately $10.3 billion in present value over thirteen years to public water systems for PFAS remediation, and DuPont, Chemours, and Corteva agreed to approximately $1.185 billion with public water providers. But those settlements resolve municipal water-system contamination claims. They are separate from the personal-injury cases. A person with kidney cancer is not covered by the water-system money. The injury cases are still being fought.
Who Can Be Held Accountable: The Defendant Structure
The AFFF and PFAS litigation involves a web of defendants, each with a different role and a different theory of liability. Understanding this structure is essential because naming the wrong defendant — or missing the right one — can sink a case.
AFFF manufacturers face product-liability claims for designing, manufacturing, and selling PFAS-containing firefighting foam. The theories include design defect — the foam was unreasonably dangerous because the environmental persistence, bioaccumulation, and toxicity of PFAS created foreseeable health risks that could have been mitigated with fluorine-free alternatives — and failure to warn — the manufacturers did not adequately warn military and civilian users of the health risks associated with PFAS exposure, despite internal corporate research that may have identified these hazards earlier than public disclosures revealed. If discovery in the MDL surfaces internal corporate documents showing that manufacturers knew of PFAS health risks and concealed or minimized them, punitive damages become a real theory. The corporate-structure issue is real here: some AFFF manufacturers have undergone spinoffs, mergers, and reorganizations that shifted liability to successor entities. The right defendant is not always the company whose name was on the drum.
The U.S. Department of Defense faces negligence claims for decades of AFFF use that contaminated soil, groundwater, and drinking water at and near military installations. The DOD has been sued by states including New Mexico to force cleanup and compensate affected landowners. A public investigation found that the DOD delayed cleanup timelines at 178 sites by one to twenty years, which may support negligence and punitive damages theories. Claims directly against the DOD under the Federal Tort Claims Act face additional hurdles: the discretionary-function exception shields policy-level judgment calls, and the FTCA’s notice requirements and damage limitations can depress recovery. But the DOD’s documented knowledge of contamination — its own PFAS progress reports track 723 installations — and its documented delays in cleanup are powerful evidence in the negligence case.
PFAS chemical suppliers — the companies that produced and supplied the PFAS compounds used in AFFF formulations — may face liability for introducing hazardous substances that were foreseeably released into the environment during normal AFFF use and training. The CERCLA hazardous-substance designation of PFOA and PFOS strengthens these claims by establishing a federal framework for contamination liability.
Individual military installations and their facility leadership made site-level decisions about AFFF use frequency, training practices, storage protocols, and remediation urgency that directly shaped the contamination profile at each base. The fact that some bases were proactive about cleanup while others delayed for years shows that these were not uniform, inevitable outcomes — they were decisions made by specific people at specific facilities.
The Evidence Clock: What Is Disappearing and How Fast
In a toxic tort case, the evidence does not sit in a tow yard waiting to be photographed. It is scattered across government databases, corporate file rooms, and the declining chemistry of your own bloodstream. Every piece of it is on a clock, and some of those clocks are already running out.
Blood serum PFAS testing is the single most time-sensitive piece of evidence in your case. PFAS levels in the blood decline over time after exposure ceases — but slowly, over years. For a firefighter who retired five years ago and has not handled AFFF since, the levels are lower than they were at peak exposure but still measurable. For someone who left a contaminated community a decade ago, the levels have declined further. The window for documenting your peak or near-peak exposure is actively closing. Every month that passes without a blood serum test is a month of declining numbers that the defense will use to argue your exposure was lower than it actually was. If you have not been tested, this is the first thing to do. Not next year. Now.
Environmental sampling data — the soil, groundwater, and drinking water PFAS measurements taken at and near military installations — establishes the contamination plume, the exposure pathways, and the temporal duration of the PFAS release. The DOD’s PFAS progress report, tracking 723 installations, was last updated in September 2025. Historical sampling results should be requested immediately through the Freedom of Information Act. Agencies do not retain all historical datasets indefinitely, and the reporting schedule has already lapsed. The future frequency of public reporting under shifting EPA priorities is uncertain. FOIA requests should be filed now, before the data is archived or lost.
AFFF purchase, use, and training records at specific military installations establish the volume, frequency, and locations of AFFF use — the source term for contamination modeling and the quantification of occupational exposure for firefighters. DOD records-retention schedules vary, and older records may already be archived or destroyed. FOIA requests for these records should be filed immediately, especially given the documented cleanup delays at 178 sites. If the DOD was slow to clean up, it may also be slow to preserve the records that show why.
DOD PFAS progress reports and site assessment documents demonstrate the government’s knowledge of contamination and its remediation timeline. The finding that the DOD delayed cleanup at 178 sites by one to twenty years may support negligence and punitive damages theories. But the agency’s reporting schedules have already lapsed — the last progress report was September 2025 — and future reporting frequency under shifting EPA priorities is uncertain.
Medical records documenting your cancer diagnosis and treatment history link the specific injury to the exposure and establish damages including treatment costs, prognosis, and impact on quality of life and earning capacity. These are generally preserved by treating providers, but complete historical records may be fragmented across multiple facilities and military health systems. Pull them together now.
Internal corporate documents from AFFF manufacturers — regarding PFAS health research, risk assessments, and internal toxicity studies — may demonstrate manufacturer knowledge of PFAS health risks and support punitive damages claims for failure to warn or active concealment of hazards. These documents are typically obtained through MDL-coordinated discovery rather than individual case discovery. This is one of the most powerful reasons to be in the MDL: the coordinated discovery process reaches into corporate file rooms that an individual plaintiff could never access alone. But MDL discovery deadlines may be closing, and the bellwether trial schedule will drive the timeline. Coordination with MDL counsel is essential.
The generalist files a complaint and hopes the evidence shows up. The firm that knows this litigation sends the FOIA requests, the preservation letters, and the blood-test orders before the complaint is even drafted — because the evidence that decides these cases is dying on a schedule that does not wait for the courthouse.
What Your Case Is Worth: Damages in AFFF and PFAS Claims
Individual AFFF and PFAS toxic tort case values depend heavily on three factors: the specific diagnosis, the strength of the exposure evidence, and which defendants are identified. Cancer cases command the highest values. Medical monitoring cases — where the plaintiff has elevated PFAS blood levels but no current diagnosis — settle at lower ranges.
Based on the case-value framework for AFFF/PFAS toxic tort litigation, individual plaintiff cases range from approximately $250,000 on the low end to $5,000,000 or more on the high end. The variables that drive where a case falls in that range include:
The diagnosis. Kidney cancer and testicular cancer — the two cancers with the strongest PFAS association in the C8 Science Panel data — command the highest individual values. Thyroid disease, ulcerative colitis, and pregnancy-induced hypertension cases may be valued lower but still carry significant damages, particularly where the condition is chronic and requires lifelong treatment.
The exposure pathway. A firefighter who directly handled AFFF concentrate for twenty years has a stronger occupational exposure case than a community member whose drinking water was contaminated. Both are viable, but the dose reconstruction and the strength of the exposure evidence differ. Direct occupational exposure is easier to quantify and harder for the defense to dispute.
The defendant identification. Cases with clear manufacturer identification — where the specific AFFF brand or formulation can be traced to the plaintiff’s exposure — are stronger than cases where the manufacturer is uncertain. The MDL’s coordinated discovery process helps with manufacturer identification, but the plaintiff’s own evidence of which foam was used, where, and when is the foundation.
Economic damages include past and future medical treatment costs, lost wages, diminished earning capacity, and property devaluation for properties near contaminated sites. Cancer treatment costs — including surgery, chemotherapy, immunotherapy, and long-term monitoring — can run into the hundreds of thousands or millions of dollars depending on the cancer type, stage, and treatment protocol. For a firefighter who can no longer work because of cancer treatment or its after-effects, lost earning capacity can be the largest single damages category.
Non-economic damages include physical pain, emotional distress, loss of enjoyment of life, and anxiety about future disease development. These are particularly significant for individuals with elevated PFAS blood serum levels who face uncertain long-term health trajectories — the knowledge that a known carcinogen is sitting in your blood at elevated levels, and that cancer may develop years or decades in the future, is itself a compensable harm in many jurisdictions.
Punitive damages may be available against AFFF manufacturers if discovery reveals knowledge of PFAS health risks that was concealed or minimized. The theory is supported by public reporting of internal corporate knowledge in related PFAS litigation. If the manufacturers’ own internal research identified health risks earlier than their public disclosures, and if they failed to warn users or actively suppressed the information, punitive damages become a real exposure — and a real lever in settlement negotiations.
Medical monitoring is a separate damage category for exposed individuals who have elevated PFAS blood serum levels but no current diagnosis. These damages fund ongoing surveillance for PFAS-associated diseases — regular blood work, imaging, cancer screenings — to catch disease early if it develops. Medical monitoring cases are viable but typically settle at lower ranges than diagnosed-disease cases.
Wrongful death and survival claims apply where PFAS-exposed individuals have died from associated cancers. The availability and structure of these claims vary by state — some states allow loss-of-society damages for the family, others limit recovery to the estate’s economic losses. If you have lost a family member to kidney cancer, testicular cancer, or another PFAS-associated disease, and that person had documented AFFF exposure or lived near a contaminated installation, wrongful death claims may be available. The applicable statute of limitations for wrongful death is typically shorter than for personal injury and runs from the date of death, not the date of exposure — confirm the deadline in your state immediately.
Claims against government defendants under the Federal Tort Claims Act face additional hurdles including notice requirements and damage limitations that may depress value. The FTCA’s two-year administrative presentment deadline and six-month suit deadline are unforgiving, and the discretionary-function exception can shield policy-level decisions from liability. But the primary path for most AFFF personal-injury plaintiffs is through the MDL against the manufacturers, where the coverage tower is larger and the liability theories are more straightforward.
Past results depend on the facts of each case and do not guarantee future outcomes. The figures above are framework ranges based on the case-value analysis for this litigation, not predictions of what any individual case will recover. What your case is worth depends on your diagnosis, your exposure evidence, your medical records, and the defendants we can identify and reach.
The Defense Playbook: What to Expect and How We Counter
The manufacturers and their insurers have a playbook for AFFF and PFAS cases. It is not a surprise — it is a sequence of moves that the defense bar has refined across decades of toxic tort litigation, from asbestos to benzene to Roundup. Knowing the plays before they run is the difference between a case that settles for what it is worth and a case that settles for a fraction.
Play 1: “Everyone has PFAS in their blood.” The defense will argue that PFAS is ubiquitous — it is in the blood of nearly every American, from nonstick cookware, stain-resistant carpet, food packaging, and a hundred other sources. Therefore, they will say, you cannot prove that your PFAS levels came from AFFF or from the military base near your house rather than from your frying pan. The counter is elevated exposure. The general population has low background levels of PFAS — typically in the low single-digit parts per billion range. A firefighter who handled AFFF for twenty years, or a community member who drank contaminated well water for a decade, will have levels that are materially elevated above background. The dose-response trends in the C8 Science Panel data, the proximity to a documented contamination source, and the specific PFAS compound profile in the blood — AFFF produces a characteristic fingerprint of PFAS compounds — all work together to single out the source. The defense’s “everyone has it” argument collapses when your levels are ten or twenty times the national average and the contamination plume maps directly to your drinking-water source.
Play 2: “Your cancer was idiopathic.” Kidney cancer and testicular cancer both occur in the general population without any known PFAS exposure. The defense will argue that your cancer was bad luck — an idiopathic occurrence that cannot be traced to AFFF. This is the specific-causation battleground. The counter is the full causal chain: documented elevated exposure (blood serum levels), a recognized probable-link finding from the C8 Science Panel, the IARC classification, the dose-response literature, the absence of other significant risk factors, and the temporal relationship between exposure and diagnosis. The defense will demand specific causation — proof that this particular cancer came from this particular exposure — and the answer is built from the convergence of all these elements, not from any single piece alone. A board-certified toxicologist with PFAS-specific expertise is essential to present this convergence to a jury.
Play 3: “You waited too long.” The defense will argue that the statute of limitations has expired because the exposure happened decades ago. The counter is the discovery rule — the clock did not start until you knew or reasonably should have known that your injury was connected to PFAS exposure. For a firefighter diagnosed with kidney cancer last year, the clock may have started with the diagnosis, not with the last time he pulled the AFFF nozzle twenty years ago. But this argument has limits — some states have statutes of repose that can cut off a claim regardless of discovery, and the specific accrual rule varies by state. An attorney who knows your state’s current toxic tort accrual doctrine is essential to answering this play.
Play 4: “We followed the rules at the time.” The manufacturers will argue that AFFF met all applicable regulatory standards when it was sold and used, and that they cannot be held liable for failing to warn about risks that the government had not yet formally recognized. The counter is twofold. First, CERCLA liability is strict and retroactive — compliance with existing regulations is not a defense to contamination liability. Second, the failure-to-warn claim does not depend on whether the government had formally recognized the risk — it depends on whether the manufacturer knew or should have known about it. If internal corporate research identified PFAS health risks before public disclosure, the manufacturer’s duty to warn arose from its own knowledge, not from the EPA’s regulatory timeline.
Play 5: The recorded statement. Someone friendly — maybe an “investigator” working for the manufacturer’s insurance company — will call and ask you to “just tell us about your experience” with AFFF. The call will be recorded. Everything you say will be transcribed and dissected for inconsistencies, gaps, and admissions that can be used to minimize your exposure or undermine your credibility. The counter is simple: do not give a recorded statement without your lawyer present. The investigator is not your friend. The call is not a conversation. It is evidence collection, and it is designed to help the defense, not you.
Play 6: The quick settlement offer. A check may arrive with a release attached before your medical results are fully developed or before the MDL bellwether process has established settlement value benchmarks. The offer will seem generous in isolation and will be a fraction of what the case is worth once the full damages picture is known. The counter is patience and process. A case filed in the MDL, with preserved evidence and a complete medical record, will be valued in the context of the bellwether outcomes and the settlement framework that emerges from the coordinated litigation. A case settled early, in isolation, is settled blind.
How a Case Is Built: The Proof Story
Here is how an AFFF and PFAS toxic tort case is actually built, from the day you call to the day a number is put on the table.
Week one: preservation and testing. The day you call, the preservation letters go out — to the military installation if you are a community member, to the fire department if you are a firefighter, to any entity that may hold AFFF use records or environmental sampling data. FOIA requests are filed for the DOD’s PFAS progress reports and site-specific sampling data. You are referred for blood serum PFAS testing to document your current exposure levels before they decline further. Your medical records are requested from every treating provider — the oncologist, the urologist, the endocrinologist, the primary care doctor, the military health system if you served.
The exposure reconstruction. An environmental fate-and-transport expert traces the contamination from the source site — the fire training area, the hangar, the crash zone — to your exposure point. For a firefighter, this means documenting when, where, and how often AFFF was used, what concentration, what duration, and what route of exposure (dermal, inhalation, ingestion). For a community member, it means mapping the contamination plume from the base to your drinking water source, documenting the years you lived there, and correlating the PFAS levels in the water with the PFAS levels in your blood. This is not guesswork — it is hydrogeology, atmospheric chemistry, and dose reconstruction, done by experts who do this for a living.
The specific-causation case. A board-certified toxicologist with PFAS-specific expertise reviews your exposure history, your blood serum levels, your diagnosis, and the epidemiological literature linking PFAS to your specific condition. The toxicologist’s opinion — that your exposure to PFAS from AFFF was a substantial contributing factor in causing your disease — is the heart of the specific-causation case. Courts will apply the Daubert or Frye standard to assess the reliability of the expert’s methodology, and the defense will aggressively challenge specific causation. The battleground is clear: while general causation linking PFAS to certain cancers is increasingly supported by epidemiological literature, the defense will argue that your exposure dose was insufficient or that confounding factors explain the diagnosis. The answer is in the convergence of evidence — dose, duration, compound profile, diagnosis, probable-link findings, and the absence of alternative explanations.
The discovery process. If your case is in the MDL, coordinated discovery is already producing internal corporate documents from the AFFF manufacturers — toxicity studies, risk assessments, marketing materials, warning-label decisions, and internal communications about PFAS health risks. These documents may demonstrate manufacturer knowledge of PFAS health risks and support punitive damages claims. The MDL discovery process is far more efficient than individual case discovery because it is centralized — one set of document requests, one set of depositions, one set of expert challenges — and the results are shared across all plaintiffs in the MDL.
The bellwether and settlement framework. As bellwether trials proceed in the MDL, the results establish settlement value benchmarks. A plaintiff verdict in a kidney cancer bellwether sets a floor for kidney cancer cases. A defense verdict adjusts expectations. The settlement framework that emerges from the bellwether process is what drives resolution of the remaining inventory — your case included. This is why being in the MDL matters: your case is valued in the context of the bellwether outcomes, not in isolation.
For cases that remand to state court after MDL pretrial proceedings, venue selection and state-specific tort law — including damage caps, comparative fault rules, and statutes of limitations — will significantly influence ultimate recovery. Some states cap non-economic damages. Some have no caps. Some allow punitive damages without limitation. The state where your case is filed can materially affect what you recover, which is why early case evaluation includes a forum analysis.
Your First Steps: Evidence, Testing, and Deadlines
If you have been exposed to AFFF or PFAS — whether as a firefighter, a military service member, or a community member near a contaminated installation — there are specific steps you should take now, and specific things you should not do.
Get blood serum PFAS testing. This is the single most time-sensitive action. PFAS levels in the blood decline over time after exposure ceases. The longer you wait, the lower your levels will be, and the harder it becomes to document the full extent of your exposure. The test measures specific PFAS compounds — PFOA, PFOS, PFHxS, PFNA, and others — in your bloodstream. The results provide objective evidence that you absorbed PFAS compounds from your environment or occupational AFFF use. This is not a medical test that diagnoses disease — it is an exposure test that documents the internal dose. If you have already been tested, obtain a copy of the results. If you have not been tested, do it now.
Document your exposure history. Write down everything you can remember about when, where, and how you were exposed to AFFF or PFAS-contaminated water. For firefighters: which bases or stations did you work at? What years? How often did you train with AFFF? Did you clean trucks, flush lines, or maintain foam systems? What brand or type of foam was used? For community members: where did you live, and during what years? Did you drink from a private well or a municipal system? When did you first learn the water was contaminated? This timeline is the foundation of your exposure case, and memory fades — document it now.
Request your medical records. If you have been diagnosed with kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, or any other condition potentially linked to PFAS, obtain your complete medical records from every treating provider. The records establish the diagnosis, the treatment, the prognosis, and the impact on your ability to work and live. If you have not been diagnosed but have elevated PFAS blood levels, document your baseline health status so that any future diagnosis can be tracked back to this point.
File FOIA requests for environmental data. If you live or lived near a military installation, request the PFAS sampling data for that installation through the Freedom of Information Act. The DOD’s PFAS progress report tracks 723 installations, but the data is not always readily accessible. Historical sampling results should be requested immediately — agencies may not retain all historical datasets indefinitely, and the reporting schedule has already lapsed.
Do not sign anything from an insurance company or government representative without legal counsel. This includes releases, settlement offers, medical authorizations, and recorded-statement agreements. A release signed today can extinguish your right to sue tomorrow, and the offer that seems fair in isolation may be a fraction of what your case is worth.
Do not give a recorded statement. An investigator working for the manufacturer’s insurance company may contact you and ask you to describe your experience with AFFF. The call will be recorded. Everything you say will be used to build the defense’s case — to minimize your exposure, to find inconsistencies in your timeline, to suggest that your health problems have another cause. Do not take the call without your lawyer.
Contact an attorney who handles toxic tort litigation. The AFFF MDL is a complex, coordinated federal proceeding. The discovery is coordinated. The expert testimony is specialized. The bellwether process drives settlement value. An attorney who understands this litigation — who knows the MDL’s procedural posture, the regulatory landscape, the science of PFAS exposure and disease, and the defense playbook — is essential to maximizing your recovery. The consultation is free. The fee is contingent — we do not get paid unless we win your case. And the call costs you nothing but the time it takes to dial.
The Medicine: How PFAS Harms the Body
PFAS are persistent, bioaccumulative compounds that bind to serum proteins and concentrate in the liver and kidneys. They are not metabolized — the human body has no efficient mechanism for breaking them down. They have long half-lives in the human body, measured in years. This means that every exposure adds to the body burden, and the burden persists long after the exposure stops.
The proposed mechanisms of PFAS harm include endocrine disruption, oxidative stress, immune modulation, and interference with cell signaling pathways. PFAS compounds have been shown to affect the thyroid axis, disrupt lipid metabolism, alter immune function, and produce oxidative damage in target organs. For the cancers linked to PFAS — particularly kidney cancer and testicular cancer — the proposed mechanism involves chronic inflammation, hormonal disruption, and direct genotoxic effects from the compounds concentrating in target tissues.
The kidney is a primary target organ for PFAS because the compounds are filtered and concentrated there. PFOA has been shown to accumulate in renal tissue, and the C8 Science Panel found a probable link between PFOA and kidney cancer. Testicular cancer is the other cancer with the strongest PFAS association — the C8 panel found a probable link, and testicular tissue has been shown to concentrate PFAS compounds.
The proof problem the defense exploits in PFAS litigation is ubiquity. PFAS is in nearly everyone’s blood. The defense argues that because everyone is exposed, no single source can be identified as the cause of any individual’s disease. The counter is elevated exposure — a firefighter who handled AFFF for decades will have blood serum levels that are materially higher than the general population, and the specific PFAS compound profile in the blood may match the profile of the AFFF used at the facility. Environmental sampling data from the contamination source, residence or work history correlating with the contamination plume, and the dose-response trends in the epidemiological literature all work together to single out the source and quantify the dose.
The latency question is also significant. Unlike asbestos, where mesothelioma can take thirty to fifty years to develop, the PFAS cancer latency is still being studied. What is clear is that PFAS compounds persist in the body for years, and the diseases they are associated with — cancer, thyroid disease, ulcerative colitis — can develop over years or decades. The long half-life of PFAS in the body means that the exposure continues, in a sense, long after the external contact stops — the compounds are still in the blood, still concentrating in target organs, still doing whatever damage they do.
For families who have lost someone to a PFAS-associated cancer, the grief is compounded by the question of whether the death was preventable. If the manufacturers knew — or should have known — that their product was putting firefighters and communities at risk, and if they failed to warn or to develop safer alternatives, then the death was not random. It was the foreseeable consequence of a corporate decision. That is what the litigation is about.
Frequently Asked Questions
What is AFFF and why is it dangerous?
AFFF — aqueous film-forming foam — is a firefighting foam used to suppress jet fuel and other flammable-liquid fires. It contains per- and polyfluoroalkyl substances, or PFAS, which are synthetic chemicals that do not break down in the environment or in the human body. PFAS have been linked to kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, pregnancy-induced hypertension, and other serious health conditions. AFFF was used for decades at military bases, airports, and firefighting training facilities, and the PFAS compounds in the foam contaminated soil, groundwater, and drinking water at and near those sites.
I was a firefighter who used AFFF. How do I know if I have a case?
If you handled AFFF — whether in training, in emergency response, or in equipment maintenance — and you have been diagnosed with kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, or another condition linked to PFAS exposure, you may have a viable toxic tort claim. The strength of your case depends on the documentation of your exposure (which bases or stations, what years, how often), your blood serum PFAS levels, your medical diagnosis, and whether the manufacturer of the foam you used can be identified. A blood serum PFAS test is the single most important first step — it provides objective evidence that you absorbed PFAS compounds from your occupational exposure.
I live near a military base and my water is contaminated. Can I sue?
Yes. Community members exposed to PFAS-contaminated drinking water near military installations have actionable claims for injuries caused by the exposure. Your case depends on documenting that your drinking water source was contaminated, that you lived there during the contamination period, that your blood serum PFAS levels are elevated, and that you have a diagnosis linked to PFAS exposure. Environmental sampling data from the installation, which can be obtained through FOIA requests, is critical evidence. Property devaluation may also be a component of your damages if the contamination has affected your property value.
How long do I have to file an AFFF or PFAS lawsuit?
The statute of limitations varies by state — typically between two and six years for personal injury claims. However, most states apply the discovery rule in toxic tort cases, which means the clock may not start until you knew or reasonably should have known that your injury was connected to PFAS exposure. For many plaintiffs, that clock starts with the cancer diagnosis or when the contamination was publicly disclosed — not with the exposure itself, which may have happened decades ago. Some states have statutes of repose that can cut off a claim regardless of discovery, so it is essential to have an attorney check the specific deadline in your state. Do not assume you have plenty of time, and do not assume you are too late.
What is the AFFF MDL and how does it affect my case?
The AFFF MDL — Multidistrict Litigation No. 2873 — is a consolidation of thousands of AFFF personal-injury, wrongful-death, and property-damage claims in the U.S. District Court for the District of South Carolina before Judge Richard M. Gergel. The MDL centralizes pretrial proceedings — discovery, motion practice, expert challenges — so that shared factual and scientific questions are resolved once. Your individual case is not merged into a class action — you keep your own claim and your own right to recover. The MDL’s coordinated discovery reaches into corporate file rooms that an individual plaintiff could never access alone, and the bellwether trial process establishes settlement value benchmarks that drive resolution of the remaining cases. Being in the MDL gives your case the benefit of coordinated, efficient pretrial work — but you still need your own lawyer to protect your individual interests.
What is blood serum PFAS testing and why is it urgent?
Blood serum PFAS testing is a blood test that measures the concentration of specific PFAS compounds — PFOA, PFOS, PFHxS, PFNA, and others — in your bloodstream. It provides objective evidence that you absorbed PFAS from your environment or occupational exposure. The test is urgent because PFAS levels in the blood decline over time after exposure ceases. The longer you wait to be tested, the lower your levels will be, and the harder it becomes to document the full extent of your exposure. If you have not been tested, this is the first thing to do — not next year, now.
What if my loved one died from cancer that might be linked to PFAS?
If your family member died from kidney cancer, testicular cancer, or another condition linked to PFAS exposure, and that person had documented AFFF exposure or lived near a contaminated installation, wrongful death and survival claims may be available. The statute of limitations for wrongful death is typically shorter than for personal injury and runs from the date of death. The specific availability and structure of wrongful death damages — including loss of financial support, loss of companionship, and the decedent’s pain and suffering before death — vary by state. If you have lost someone, do not wait to contact an attorney. The deadline may already be running.
How much does it cost to hire an attorney for an AFFF case?
Nothing up front. We work on contingency — 33.33% before trial and 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free, and it is confidential. You can call us at 1-888-ATTY-911, twenty-four hours a day, seven days a week, and speak to a live person — not an answering service. We also serve families fully in Spanish. Hablamos Español.
What should I not do if I think I have an AFFF or PFAS case?
Do not give a recorded statement to any insurance company, investigator, or government representative without your lawyer present. Do not sign any release, settlement offer, or medical authorization without legal counsel. Do not post about your exposure, your diagnosis, or your case on social media — the defense will mine your posts for material to minimize your claim. Do not wait to get blood serum PFAS testing — the window for documenting your exposure levels is closing. And do not assume it is too late to file — the discovery rule may give you more time than you think, but only an attorney who knows your state’s law can confirm the deadline.
Why Attorney911
Ralph Manginello has spent 27-plus years in courtrooms, including federal court. He was a journalist before he was a lawyer — he knows how to find the story the evidence tells, and he knows how to tell it to a jury. He is admitted to the U.S. District Court for the Southern District of Texas, and the firm takes cases across the country in coordination with local counsel where required. He is a member of the Texas Trial Lawyers Association and the Houston Bar Association, and he has spent his career in the courtroom fighting for people who were failed by institutions and corporations that should have protected them.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims from people exactly like the ones we now represent. He knows claim valuation from the inside, including how reserves are set in the first forty-eight hours, how recorded statements are engineered, and how surveillance and social-media monitoring are deployed. He now uses that knowledge for injured clients. He is fluent in Spanish and conducts full consultations without an interpreter. The firm serves families fully in both languages.
We handle toxic tort claims — including AFFF and PFAS exposure cases, benzene and leukemia cases, asbestos and mesothelioma cases, and other environmental and occupational chemical exposure matters. The medicine, the corporate-accountability fight, the catastrophic-injury and wrongful-death work — these are what we do. The firm has recovered more than $50 million for clients across its practice. Past results depend on the facts of each case and do not guarantee future outcomes.
The call is free. The consultation is confidential. The fee is contingent — we do not get paid unless we win your case. Call 1-888-ATTY-911, twenty-four hours a day, seven days a week. You will speak to a live person, not an answering service. And if we are not the right fit for your case, we will tell you — honestly and without pressure.
The evidence in your case is on a clock. The PFAS in your blood is declining. The records at the base are aging. The manufacturers’ internal documents are being produced in the MDL, but the discovery deadlines are moving. The day you call is the day the clock starts working for you instead of against you. Call now.